Cercano Management LLC recently announced the acquisition of new stake in Sigilon Therapeutics Inc. (NASDAQ:SGTX). This fresh investment now brings its stake to 2.73% valued currently at $0.96 million. In addition, Millennium Management LLC raised its holdings by 1360.0 to 0.23 million shares. And Renaissance Technologies LLC has lifted its position by 18.42% or 28794.0 shares – to 0.19 million shares.
With over 5.85 million Sigilon Therapeutics Inc. (SGTX) shares trading Tuesday and a closing price of $1.16 on the day, the dollar volume was approximately $6.78 million. The shares have shown a positive half year performance of 71.85% and its price on 03/14/23 gained nearly 64.84%. Currently, there are 32.40M common shares owned by the public and among those 28.13M shares have been available to trade.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for SGTX have a consensus price objective of $3.50. The analysts have set the share’s price value over the next 12 months at a high of $7.00 and a low of $0.50. The average price target is 66.86% above its recent price level and a downside to the estimated low will see the stock lose -132.0% over that period. But an upside of 83.43% will see the stock hit the forecast high price target while median target price for the stock is $2.00.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Sigilon Therapeutics Inc. are Canada Pension Plan, BlackRock Health Sciences Trust I, and Fidelity Growth Company Fund. Canada Pension Plan owns 1.49 million shares of the company’s stock, all valued at over $1.62 million. The company sold 10162.0 shares recently to bring their total holdings to about 4.58% of the shares outstanding. Fidelity Growth Company Fund sold 6460.0 shares to bring its total holdings to over 0.37 million shares at a value of $0.41 million. Fidelity Growth Company Fund now owns shares totaling to 1.15% of the shares outstanding.
Shares of Sigilon Therapeutics Inc. (NASDAQ: SGTX) opened at $0.73, up $0.03 from a prior closing price of $0.70. However, the script later moved the day high at 1.3100, up 64.84%. The company’s stock has a 5-day price change of -14.07% and 236.23% over the past three months. SGTX shares are trading 231.43% year to date (YTD), with the 12-month market performance down to -11.45% lower. It has a 12-month low price of $0.29 and touched a high of $1.75 over the same period. SGTX has an average intraday trading volume of 304.76K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 19.71%, 61.37%, and 78.81% respectively.
Institutional ownership of Sigilon Therapeutics Inc. (NASDAQ: SGTX) shares accounts for 52.20% of the company’s 32.40M shares outstanding. Mutual fund holders own 10.95%, while other institutional holders and individual stakeholders account for 8.74% and 0.37% respectively.
It has a market capitalization of $44.52M. The earnings-per-share (ttm) stands at -$1.69. Price movements for the stock have been influenced by the stock’s volatility, which stands at 40.23% over the week and 23.47% over the month.
Analysts forecast that Sigilon Therapeutics Inc. (SGTX) will achieve an EPS of -$0.38 for the current quarter, -$0.34 for the next quarter and -$1.28 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.66 while analysts give the company a high EPS estimate of -$0.25. Comparatively, EPS for the current quarter was -$0.55 a year ago. Earnings per share for the fiscal year are expected to decrease by -39.80%, and 14.70% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Sigilon Therapeutics Inc. (SGTX) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 2 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the SGTX, a number of firms have released research notes about the stock. Jefferies stated their Hold rating for the stock in a research note on November 30, 2021, with the firm’s price target at $15-$4. BTIG Research coverage for the Sigilon Therapeutics Inc. (SGTX) stock in a research note released on October 29, 2021 offered a Buy rating with a price target of $14. Jefferies was of a view on August 02, 2021 that the stock is Buy, while Morgan Stanley gave the stock Equal-Weight rating on December 29, 2020, issuing a price target of $45. Jefferies on their part issued Buy rating on December 29, 2020.
